Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Claims cover method of treating a viral infection with a lectin-binding carbohydrate
BOSTON, MASSACHUSETTS, October 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
Google Patent link:
The glycovirology platform is a market forming technology with potentially wide-reachingimplications. This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic. The first antiviral agents were nucleoside/nucleotide reverse transcriptase inhibitors (NRTI’s) which would make their way to the infected cells and prevent the cell from reading the viral code and converting it into copying DNA. As drug resistance emerged, protease inhibitors which cleave the polypeptides into usable viral proteins were blocked to disrupt the viral replication process. Eventually a combination of therapies known as Highly Active Antiretroviral therapy (HAART) became the standard of care for the past 25 years. The current Mechanism of Action (MOA) of almost all antivirals traces its roots to the disruption of the viral replication cycle. Bioxytran, with its complex carbohydrate entry inhibitor, is a next generation antiviral which prevents cellular entry by neutralizing the virus outside of the cell so it never gets in the cells to replicate.
Bioxytran has completed 3 successful in-vitro tests for COVID-19, RSV, and H1N1 that demonstrate the potential of our galectin antagonist to be used as a broad-spectrum antiviral.Further research is needed to determine the boundaries of the broad-spectrum activity. Many of the indications claimed in the patent are based on scientific research that made the case that galectins are involved in the cellular entry mechanism and that blocking them interferes with their ability to enter the cell, or that galectins are involved in the overall disease pathology. When forming our initial hypothesis in March 2020 that a galectin antagonist could interfere with the SARS-CoV-2 spike protein, the existing research at the time led us to see the similarities between the HIV spike protein and the SARS-CoV-2 spike protein. Since our initial thesis was published in March 2020 over 40 scientific journal articles have been published on the topic.
This is possibly a groundbreaking patent because we believe it is the first of its kind in the field of glycovirology. The broad claims in terms of combinations of molecules and the number of viruses likely affected a present and pre-eminent position in this field of research. Being the first in the field and progressing closer to a registrational trial demonstrates the Company is a leader in drug development in this field. This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio. We believe according to this patent, if issued any future drug developers looking to enter the field of glycovirology will need to license the necessary technology. This field of research holds so much promise there exists the potential for there to be a rush to develop drugs which could rival that of the movement to develop antibiotics which occurred after the first use of penicillin.
“This patent represents a huge expansion of our intellectual property in the field of glycovirology,” said Dr. Leslie Ajayi. “This patent indicates that our galectin antagonists represent potentially one of the biggest platform technologies in existence. How many big pharmas that have over 60 disease indications can say it comes from just one platform technology? This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella. It also covers very deadly viruses like Ebola, Marburg, and Nipa. We are just scratching the surface and feel that follow on research is necessary to prove the mechanism and overall importance of this technology in the biotech field.”
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.